1. Hulin A, Hego A, Lancellotti P, Oury C. Advances in pathophysiology of calcific aortic valve disease propose novel molecular therapeutic targets. Front Cardiovasc Med 2018; 5: 21.
2. Hisamatsu T, Miura K, Fujiyoshi A, Kadota A, Miyagawa N,
Satoh A, et al. Serum magnesium, phosphorus, and calcium levels
and subclinical calcific aortic valve disease: A population-based
study. Atherosclerosis 2018; 273: 145 – 152.
3. Lerman DA, Prasad S, Alotti N. Calcific aortic valve disease:
Molecular mechanisms and therapeutic approaches. Eur Cardiol
2015; 10: 108 – 112.
4. Peeters FECM, Meex SJR, Dweck MR, Aikawa E, Crijns HJGM,
Schurgers LJ, et al. Calcific aortic valve stenosis: Hard disease in
the heart: A biomolecular approach towards diagnosis and treatment. Eur Heart J 2017; 39: 2618 – 2624.
5. Koos R, Mahnken AH, Sinha AM, Wildberger JE, Hoffmann
R, Kühl HP. Aortic valve calcification as a marker for aortic
stenosis severity: Assessment on 16-MDCT. AJR Am J Roentgenol
2004; 183: 1813 – 1818.
6. Liu F, Coursey CA, Grahame-Clarke C, Sciacca RR,
Rozenshtein A, Homma S, et al. Aortic valve calcification as an
incidental finding at CT of the elderly: Severity and location as
predictors of aortic stenosis. AJR Am J Roentgenol 2006; 186:
342 – 349.
7. Pohle K, Maffert R, Ropers D, Moshage W, Stilianakis N, Daniel
WG, et al. Progression of aortic valve calcification: Association
with coronary atherosclerosis and cardiovascular risk factors.
Circulation 2001; 104: 1927 – 1932.
8. Shimizu K, Yamamoto M, Koyama Y, Kodama A, Sato H, Kano
S, et al. Usefulness of routine aortic valve calcium score measurement for risk stratification of aortic stenosis and coronary artery
disease in patients scheduled cardiac multislice computed tomography. Int J Cardiol Heart Vasc 2015; 9: 95 – 99.
9. Otvos JD, Mora S, Shalaurova I, Greenland P, Mackey RH,
Goff DC Jr. Clinical implications of discordance between lowdensity lipoprotein cholesterol and particle number. J Clin
Lipidol 2011; 5: 105 – 113.
10. Zaid M, Fujiyoshi A, Miura K, Abbott RD, Okamura T,
Takashima N, et al. High-density lipoprotein particle concentration and subclinical atherosclerosis of the carotid arteries in
Circulation Journal Vol.85, July 2021
1082
VU T et al.
Japanese men. Atherosclerosis 2015; 239: 444 – 450.
11. Zaid M, Miura K, Fujiyoshi A, Abbott RD, Hisamatsu T,
Kadota A, et al. Associations of serum LDL particle concentration with carotid intima-media thickness and coronary artery
calcification. J Clin Lipidol 2016; 10: 1195 – 1202.e1191.
12. Mackey RH, Greenland P, Goff DC Jr, Lloyd-Jones D, Sibley
CT, Mora S. High-density lipoprotein cholesterol and particle
concentrations, carotid atherosclerosis, and coronary events:
MESA (Multi-Ethnic Study of Atherosclerosis). J Am Coll Cardiol 2012; 60: 508 – 516.
13. Grabner M, Winegar DA, Punekar RS, Quimbo RA, Cziraky
MJ, Cromwell WC. Cost effectiveness of achieving targets of
low-density lipoprotein particle number versus low-density lipoprotein cholesterol level. Am J Cardiol 2017; 119: 404 – 409.
14. Kadota A, Miura K, Okamura T, Fujiyoshi A, Ohkubo T,
Kadowaki T, et al. Carotid intima-media thickness and plaque in
apparently healthy Japanese individuals with an estimated 10-year
absolute risk of CAD death according to the Japan Atherosclerosis Society (JAS) guidelines 2012: The Shiga Epidemiological
Study of Subclinical Atherosclerosis (SESSA). J Atheroscler
Thromb 2013; 20: 755 – 766.
15. Ueshima H, Kadowaki T, Hisamatsu T, Fujiyoshi A, Miura K,
Ohkubo T, et al. Lipoprotein-associated phospholipase A2 is
related to risk of subclinical atherosclerosis but is not supported
by Mendelian randomization analysis in a general Japanese
population. Atherosclerosis 2016; 246: 141 – 147.
16. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the
concentration of low-density lipoprotein cholesterol in plasma,
without use of the preparative ultracentrifuge. Clin Chem 1972;
18: 499 – 502.
17. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification
of the CKD Epidemiology Collaboration (CKD-EPI) equation
for Japanese: Accuracy and use for population estimates. Am J
Kidney Dis 2010; 56: 32 – 38.
18. Imai E, Yasuda Y, Makino H. Japan Association of Chronic
Kidney Disease Initiatives (J-CKDI). Japan Med Assoc J 2011;
54: 403 – 405.
19. Jeyarajah EJ, Cromwell WC, Otvos JD. Lipoprotein particle
analysis by nuclear magnetic resonance spectroscopy. Clin Lab
Med 2006; 26: 847 – 870.
20. Otvos JD, Jeyarajah EJ, Cromwell WC. Measurement issues
related to lipoprotein heterogeneity. Am J Cardiol 2002; 90:
22i – 29i.
21. Kashiwagi A, Kasuga M, Araki E, Oka Y, Hanafusa T, Ito H, et
al. International clinical harmonization of glycated hemoglobin in
Japan: From Japan Diabetes Society to National Glycohemoglobin
Standardization Program values. J Diabetes Investig 2012; 3: 39 – 40.
22. Hisamatsu T, Fujiyoshi A, Miura K, Ohkubo T, Kadota A,
Kadowaki S, et al. Lipoprotein particle profiles compared with
standard lipids in association with coronary artery calcification
in the general Japanese population. Atherosclerosis 2014; 236:
237 – 243.
23. Agatston AS, Janowitz WR, Hildner FJ, Zusmer NR, Viamonte
M Jr, Detrano R. Quantification of coronary artery calcium using
ultrafast computed tomography. J Am Coll Cardiol 1990; 15:
827 – 832.
24. Katz R, Wong ND, Kronmal R, Takasu J, Shavelle DM,
Probstfield JL, et al. Features of the metabolic syndrome and
diabetes mellitus as predictors of aortic valve calcification in the
Multi-Ethnic Study of Atherosclerosis. Circulation 2006; 113:
2113 – 2119.
25. Linefsky JP, O’Brien KD, Sachs M, Katz R, Eng J, Michos ED,
et al. Serum phosphate is associated with aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis (MESA).
Atherosclerosis 2014; 233: 331 – 337.
26. Owens DS, Katz R, Takasu J, Kronmal R, Budoff MJ, O’Brien
KD. Incidence and progression of aortic valve calcium in the
Multi-Ethnic Study of Atherosclerosis (MESA). Am J Cardiol
2010; 105: 701 – 708.
27. Tehrani DM, Zhao Y, Blaha MJ, Mora S, Mackey RH, Michos
ED, et al. Discordance of low-density lipoprotein and highdensity lipoprotein cholesterol particle versus cholesterol concentration for the prediction of cardiovascular disease in patients
with metabolic syndrome and diabetes mellitus (from the MultiEthnic Study of Atherosclerosis [MESA]). Am J Cardiol 2016;
117: 1921 – 1927.
28. Alberti KG, Zimmet P, Shaw J. The metabolic syndrome: A new
worldwide definition. Lancet 2005; 366: 1059 – 1062.
29. Taki K, Nishio K, Hamajima N, Niwa T. Metabolic syndrome
defined by new criteria in Japanese is associated with increased
liver enzymes and C-reactive protein. Nagoya J Med Sci 2008;
70: 1 – 9.
30. Owens DS, Katz R, Johnson E, Shavelle DM, Probstfield JL,
Takasu J, et al. Interaction of age with lipoproteins as predictors
of aortic valve calcification in the Multi-Ethnic Study of Atherosclerosis. Arch Intern Med 2008; 168: 1200 – 1207.
31. Cromwell WC, Otvos JD, Keyes MJ, Pencina MJ, Sullivan L,
Vasan RS, et al. LDL particle number and risk of future cardiovascular disease in the Framingham Offspring Study: Implications for LDL Management. J Clin Lipidol 2007; 1: 583 – 592.
32. Shavelle DM, Takasu J, Budoff MJ, Mao S, Zhao XQ, O’Brien
KD. HMG CoA reductase inhibitor (statin) and aortic valve
calcium. Lancet 2002; 359: 1125 – 1126.
33. Rosenhek R, Rader F, Loho N, Gabriel H, Heger M, Klaar U,
et al. Statins but not angiotensin-converting enzyme inhibitors
delay progression of aortic stenosis. Circulation 2004; 110: 1291 – 1295.
34. Thiago L, Tsuji SR, Nyong J, Puga ME, Gois AF, Macedo CR,
et al. Statins for aortic valve stenosis. Cochrane Database Syst
Rev 2016; 9: Cd009571.
35. Olgun Küçük H, Küçük U, Demirtaş C, Özdemir M. Role of
serum high density lipoprotein levels and functions in calcific
aortic valve stenosis progression. Int J Clin Exp Med 2015; 8:
22543 – 22549.
36. Tan HC, Tai ES, Sviridov D, Nestel PJ, Ng C, Chan E, et al.
Relationships between cholesterol efflux and high-density lipoprotein particles in patients with type 2 diabetes mellitus. J Clin
Lipidol 2011; 5: 467 – 473.
37. Linsel-Nitschke P, Jansen H, Aherrarhou Z, Belz S, Mayer B,
Lieb W, et al. Macrophage cholesterol efflux correlates with
lipoprotein subclass distribution and risk of obstructive coronary
artery disease in patients undergoing coronary angiography.
Lipids Health Dis 2009; 8: 14.
38. Sigdel M, Yadav BK, Gyawali P, Regmi P, Baral S, Regmi SR,
et al. Non-high density lipoprotein cholesterol versus low density
lipoprotein cholesterol as a discriminating factor for myocardial
infarction. BMC Res Notes 2012; 5: 640.
39. Sniderman AD, Williams K, Contois JH, Monroe HM, McQueen
MJ, de Graaf J, et al. A meta-analysis of low-density lipoprotein
cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B as markers of cardiovascular risk. Circ Cardiovasc
Qual Outcomes 2011; 4: 337 – 345.
Supplementary Files
Please find supplementary file(s);
http://dx.doi.org/10.1253/circj.CJ-20-1090
Circulation Journal Vol.85, July 2021
...
論文の公開元へ
